ATLANTA, March 04, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ:VTYX). The lawsuit alleges Defendants made materially false and misleading statements and/or failed to disclose material adverse information in its Offering Documents and throughout the Class Period regarding the Company's business, operations, and prospects, including allegations that: (i) VTX958 was less effective in treating psoriasis than Defendants had led investors to believe; (ii) as a result, VTX958's clinical and/or commercial prospects were overstated; (iii) accordingly, Ventyx had misrepresented its ability ...
VTYX) Investors – Nationally Ranked Investors' Rights Firm Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm>Full story available on Benzinga.com